ZipBio and MeiraGTx Partner to Develop AAV Gene Therapy for Geographic Atrophy

ZipBio and MeiraGTx have entered into an exclusive license agreement to develop a first-in-class AAV gene therapy targeting geographic atrophy, a severe form of age-related macular degeneration. The collaboration aims to leverage ZipBio’s proprietary technology alongside MeiraGTx’s expertise in gene therapy development and manufacturing. This partnership represents a significant step toward addressing the unmet medical needs associated with this progressive eye condition.

Under the terms of the agreement, ZipBio will provide its innovative platform for developing adeno-associated virus (AAV)-based therapies, while MeiraGTx will oversee clinical development, regulatory approvals, and commercialization efforts. Geographic atrophy currently lacks effective treatment options, making it a critical focus for therapeutic innovation. Both companies aim to combine their resources and expertise to advance research and potentially deliver new solutions for patients affected by this debilitating disease.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: February 3, 2026

Author

GOAI